VNDA
NASDAQ · Biotechnology
Vanda Pharmaceuticals Inc
$7.12
-1.45 (-16.92%)
Open$8.59
Previous Close$8.57
Day High$8.67
Day Low$7.05
52W High$9.60
52W Low$3.81
Volume—
Avg Volume1.40M
Market Cap374.68M
P/E Ratio—
EPS$-1.43
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+117.0% upside
Current
$7.12
$7.12
Target
$15.45
$15.45
$11.33
$15.45 avg
$18.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 218.56M | 241.66M | 122.09M |
| Net Income | -20,779,812 | -20,678,716 | 12.67M |
| Profit Margin | -9.5% | -9.0% | 10.4% |
| EBITDA | -17,205,684 | -18,073,197 | 21.61M |
| Free Cash Flow | — | — | 20.08M |
| Rev Growth | -9.6% | -9.6% | +22.8% |
| Debt/Equity | 0.01 | 0.01 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |